-
1
-
-
77951698149
-
Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling
-
Rey, S., Semenza, G.L., Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc. Res. 86 (2010), 236–242.
-
(2010)
Cardiovasc. Res.
, vol.86
, pp. 236-242
-
-
Rey, S.1
Semenza, G.L.2
-
2
-
-
0028929803
-
Angiogenesis in cancer, vascular, rheumatoid and other disease
-
Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995), 27–30.
-
(1995)
Nat. Med.
, vol.1
, pp. 27-30
-
-
Folkman, J.1
-
3
-
-
79957534572
-
Targeting hypoxia in cancer therapy
-
Wilson, W.R., Hay, M.P., Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11 (2011), 393–410.
-
(2011)
Nat. Rev. Cancer
, vol.11
, pp. 393-410
-
-
Wilson, W.R.1
Hay, M.P.2
-
4
-
-
77954836067
-
The tumor microenvironment in non-small-cell lung cancer
-
Graves, E.E., et al. The tumor microenvironment in non-small-cell lung cancer. Semin. Radiat. Oncol. 20 (2010), 156–163.
-
(2010)
Semin. Radiat. Oncol.
, vol.20
, pp. 156-163
-
-
Graves, E.E.1
-
5
-
-
84929358929
-
Combined effects of pericytes in the tumor microenvironment
-
Ribeiro, A.L., Okamoto, O.K., Combined effects of pericytes in the tumor microenvironment. Stem Cells Int., 2015, 2015, 868475.
-
(2015)
Stem Cells Int.
, vol.2015
, pp. 868475
-
-
Ribeiro, A.L.1
Okamoto, O.K.2
-
6
-
-
84992459052
-
Molecular targeting of hypoxia in radiotherapy
-
Rey, S., et al. Molecular targeting of hypoxia in radiotherapy. Adv. Drug Deliv. Rev. 109 (2017), 45–62.
-
(2017)
Adv. Drug Deliv. Rev.
, vol.109
, pp. 45-62
-
-
Rey, S.1
-
7
-
-
85004065577
-
Hypoxia-inducible factors: master regulators of cancer progression
-
Schito, L., Semenza, G.L., Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer 2 (2016), 758–770.
-
(2016)
Trends Cancer
, vol.2
, pp. 758-770
-
-
Schito, L.1
Semenza, G.L.2
-
8
-
-
84954569855
-
Ten years of anti-vascular endothelial growth factor therapy
-
Ferrara, N., Adamis, A.P., Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15 (2016), 385–403.
-
(2016)
Nat. Rev. Drug Discov.
, vol.15
, pp. 385-403
-
-
Ferrara, N.1
Adamis, A.P.2
-
9
-
-
85001075180
-
mTOR signaling confers resistance to targeted cancer drugs
-
Guri, Y., Hall, M.N., mTOR signaling confers resistance to targeted cancer drugs. Trends Cancer 2 (2016), 688–697.
-
(2016)
Trends Cancer
, vol.2
, pp. 688-697
-
-
Guri, Y.1
Hall, M.N.2
-
10
-
-
84912096468
-
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia
-
Jain, R.K., Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26 (2014), 605–622.
-
(2014)
Cancer Cell
, vol.26
, pp. 605-622
-
-
Jain, R.K.1
-
11
-
-
84876993950
-
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers
-
Jain, R.K., Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 31 (2013), 2205–2218.
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 2205-2218
-
-
Jain, R.K.1
-
12
-
-
84890282284
-
Benefits of vascular normalization are dose and time dependent: Letter
-
Huang, Y., et al. Benefits of vascular normalization are dose and time dependent: Letter. Cancer Res. 73 (2013), 7144–7146.
-
(2013)
Cancer Res.
, vol.73
, pp. 7144-7146
-
-
Huang, Y.1
-
13
-
-
84855931910
-
Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs
-
Van der Veldt, A.A.M., et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21 (2012), 82–91.
-
(2012)
Cancer Cell
, vol.21
, pp. 82-91
-
-
Van der Veldt, A.A.M.1
-
14
-
-
84920445585
-
89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment
-
Oosting, S.F., et al. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J. Nucl. Med. 56 (2015), 63–69.
-
(2015)
J. Nucl. Med.
, vol.56
, pp. 63-69
-
-
Oosting, S.F.1
-
15
-
-
84878609062
-
Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake
-
Arjaans, M., et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res. 73 (2013), 3347–3355.
-
(2013)
Cancer Res.
, vol.73
, pp. 3347-3355
-
-
Arjaans, M.1
-
16
-
-
84897386715
-
Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model
-
Heijmen, L., et al. Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media Mol. Imaging 9 (2014), 237–245.
-
(2014)
Contrast Media Mol. Imaging
, vol.9
, pp. 237-245
-
-
Heijmen, L.1
-
17
-
-
84877799305
-
Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies
-
Heskamp, S., et al. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int. J. Cancer 133 (2013), 307–314.
-
(2013)
Int. J. Cancer
, vol.133
, pp. 307-314
-
-
Heskamp, S.1
-
18
-
-
33645735004
-
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia
-
Franco, M., et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res. 66 (2006), 3639–3648.
-
(2006)
Cancer Res.
, vol.66
, pp. 3639-3648
-
-
Franco, M.1
-
19
-
-
84989159343
-
Antiangiogenic therapy in oncology: current status and future directions
-
Jayson, G.C., et al. Antiangiogenic therapy in oncology: current status and future directions. Lancet 388 (2016), 518–529.
-
(2016)
Lancet
, vol.388
, pp. 518-529
-
-
Jayson, G.C.1
-
20
-
-
84991735476
-
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
-
Frentzas, S., et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat. Med. 22 (2016), 1294–1302.
-
(2016)
Nat. Med.
, vol.22
, pp. 1294-1302
-
-
Frentzas, S.1
-
21
-
-
84992401796
-
Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma
-
Kuczynski, E.A., et al. Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma. J. Natl. Cancer Inst., 108, 2016, djw030.
-
(2016)
J. Natl. Cancer Inst.
, vol.108
, pp. djw030
-
-
Kuczynski, E.A.1
-
22
-
-
85015353538
-
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
-
Kuczynski, E.A., Kerbel, R.S., Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. Chin. J. Cancer, 35, 2016, 97.
-
(2016)
Chin. J. Cancer
, vol.35
, pp. 97
-
-
Kuczynski, E.A.1
Kerbel, R.S.2
-
23
-
-
85006889134
-
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models
-
Bridgeman, V.L., et al. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J. Pathol. 241 (2017), 362–374.
-
(2017)
J. Pathol.
, vol.241
, pp. 362-374
-
-
Bridgeman, V.L.1
-
24
-
-
84866524036
-
Tumor cell vasculogenic mimicry: from controversy to therapeutic promise
-
Seftor, R.E.B., et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am. J. Pathol. 181 (2012), 1115–1125.
-
(2012)
Am. J. Pathol.
, vol.181
, pp. 1115-1125
-
-
Seftor, R.E.B.1
-
25
-
-
84961241587
-
The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment
-
Li, S., et al. The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment. Biomed. Pharmacother. 80 (2016), 127–135.
-
(2016)
Biomed. Pharmacother.
, vol.80
, pp. 127-135
-
-
Li, S.1
-
26
-
-
79953244361
-
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
-
Ebos, J.M.L., Kerbel, R.S., Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8 (2011), 210–221.
-
(2011)
Nat. Rev. Clin. Oncol.
, vol.8
, pp. 210-221
-
-
Ebos, J.M.L.1
Kerbel, R.S.2
-
27
-
-
84926205960
-
CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer
-
Conley, S.J., et al. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res. Treat. 150 (2015), 559–567.
-
(2015)
Breast Cancer Res. Treat.
, vol.150
, pp. 559-567
-
-
Conley, S.J.1
-
28
-
-
84863422466
-
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
-
Rapisarda, A., Melillo, G., Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat. Rev. Clin. Oncol. 9 (2012), 378–390.
-
(2012)
Nat. Rev. Clin. Oncol.
, vol.9
, pp. 378-390
-
-
Rapisarda, A.1
Melillo, G.2
-
29
-
-
20544437870
-
Overview of tumor cell chemoresistance mechanisms
-
Gatti, L., Zunino, F., Overview of tumor cell chemoresistance mechanisms. Methods Mol. Med. 111 (2005), 127–148.
-
(2005)
Methods Mol. Med.
, vol.111
, pp. 127-148
-
-
Gatti, L.1
Zunino, F.2
-
30
-
-
84872243145
-
Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance
-
Levitzki, A., Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu. Rev. Pharmacol. Toxicol. 53 (2013), 161–185.
-
(2013)
Annu. Rev. Pharmacol. Toxicol.
, vol.53
, pp. 161-185
-
-
Levitzki, A.1
-
31
-
-
84867531311
-
Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma
-
Liu, L., et al. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin. Cancer Res. 18 (2012), 5662–5671.
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 5662-5671
-
-
Liu, L.1
-
32
-
-
77952671059
-
Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors
-
Nilsson, M.B., et al. Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 29 (2010), 2938–2949.
-
(2010)
Oncogene
, vol.29
, pp. 2938-2949
-
-
Nilsson, M.B.1
-
33
-
-
84867087464
-
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
-
Schito, L., et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E2707–E2716.
-
(2012)
Proc. Natl. Acad. Sci. U. S. A.
, vol.109
, pp. E2707-E2716
-
-
Schito, L.1
-
34
-
-
84938117930
-
2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma
-
Lin, H., et al. 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma. Tumour Biol. 37 (2016), 381–391.
-
(2016)
Tumour Biol.
, vol.37
, pp. 381-391
-
-
Lin, H.1
-
35
-
-
84991054855
-
Clinical pharmacokinetics and pharmacodynamics of cabozantinib
-
Lacy, S.A., et al. Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clin. Pharmacokinet. 56 (2017), 477–491.
-
(2017)
Clin. Pharmacokinet.
, vol.56
, pp. 477-491
-
-
Lacy, S.A.1
-
36
-
-
60649087564
-
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
-
Ebos, J.M.L., et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (2009), 232–239.
-
(2009)
Cancer Cell
, vol.15
, pp. 232-239
-
-
Ebos, J.M.L.1
-
37
-
-
84887456534
-
Role of endothelial cell metabolism in vessel sprouting
-
De Bock, K., et al. Role of endothelial cell metabolism in vessel sprouting. Cell Metab. 18 (2013), 634–647.
-
(2013)
Cell Metab.
, vol.18
, pp. 634-647
-
-
De Bock, K.1
-
38
-
-
85069238583
-
Endothelial cell metabolism: parallels and divergences with cancer cell metabolism
-
Verdegem, D., et al. Endothelial cell metabolism: parallels and divergences with cancer cell metabolism. Cancer Metab., 2, 2014, 19.
-
(2014)
Cancer Metab.
, vol.2
, pp. 19
-
-
Verdegem, D.1
-
39
-
-
85012011397
-
Understanding the intersections between metabolism and cancer biology
-
Vander Heiden, M.G., DeBerardinis, R.J., Understanding the intersections between metabolism and cancer biology. Cell 168 (2017), 657–669.
-
(2017)
Cell
, vol.168
, pp. 657-669
-
-
Vander Heiden, M.G.1
DeBerardinis, R.J.2
-
40
-
-
84989959246
-
Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities
-
Goveia, J., et al. Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities. EMBO Mol. Med. 8 (2016), 1134–1142.
-
(2016)
EMBO Mol. Med.
, vol.8
, pp. 1134-1142
-
-
Goveia, J.1
-
41
-
-
85013483792
-
Hypoxia and cellular metabolism in tumour pathophysiology
-
Parks, S.K., et al. Hypoxia and cellular metabolism in tumour pathophysiology. J. Physiol. 595 (2017), 2439–2450.
-
(2017)
J. Physiol.
, vol.595
, pp. 2439-2450
-
-
Parks, S.K.1
-
42
-
-
85016143129
-
The role of fatty acid β-oxidation in lymphangiogenesis
-
Wong, B.W., et al. The role of fatty acid β-oxidation in lymphangiogenesis. Nature 542 (2017), 49–54.
-
(2017)
Nature
, vol.542
, pp. 49-54
-
-
Wong, B.W.1
-
43
-
-
84975166609
-
Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics
-
Navarro, P., et al. Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics. Cell Rep. 15 (2016), 2705–2718.
-
(2016)
Cell Rep.
, vol.15
, pp. 2705-2718
-
-
Navarro, P.1
-
44
-
-
84965018493
-
HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies
-
Subhani, S., et al. HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies. Angiogenesis 19 (2016), 257–273.
-
(2016)
Angiogenesis
, vol.19
, pp. 257-273
-
-
Subhani, S.1
-
45
-
-
84872799328
-
Recent agents targeting HIF-1α for cancer therapy
-
Hu, Y., et al. Recent agents targeting HIF-1α for cancer therapy. J. Cell. Biochem. 114 (2013), 498–509.
-
(2013)
J. Cell. Biochem.
, vol.114
, pp. 498-509
-
-
Hu, Y.1
-
46
-
-
0024316466
-
DNA topoisomerase poisons as antitumor drugs
-
Liu, L.F., DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58 (1989), 351–375.
-
(1989)
Annu. Rev. Biochem.
, vol.58
, pp. 351-375
-
-
Liu, L.F.1
-
47
-
-
0028006314
-
Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy
-
Husain, I., et al. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 54 (1994), 539–546.
-
(1994)
Cancer Res.
, vol.54
, pp. 539-546
-
-
Husain, I.1
-
48
-
-
0036682284
-
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway
-
Rapisarda, A., et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62 (2002), 4316–4324.
-
(2002)
Cancer Res.
, vol.62
, pp. 4316-4324
-
-
Rapisarda, A.1
-
49
-
-
70349135129
-
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma
-
Merritt, W.M., et al. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol. Ther. 8 (2009), 1596–1603.
-
(2009)
Cancer Biol. Ther.
, vol.8
, pp. 1596-1603
-
-
Merritt, W.M.1
-
50
-
-
84952303328
-
Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
-
Di Desidero, T., et al. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. Oncotarget 6 (2015), 42396–42410.
-
(2015)
Oncotarget
, vol.6
, pp. 42396-42410
-
-
Di Desidero, T.1
-
51
-
-
85008399987
-
Novel ABCG2 antagonists reverse topotecan-mediated chemotherapeutic resistance in ovarian carcinoma xenografts
-
Ricci, J.W., et al. Novel ABCG2 antagonists reverse topotecan-mediated chemotherapeutic resistance in ovarian carcinoma xenografts. Mol. Cancer Ther. 15 (2016), 2853–2862.
-
(2016)
Mol. Cancer Ther.
, vol.15
, pp. 2853-2862
-
-
Ricci, J.W.1
-
52
-
-
84961205899
-
Hypoxia regulates ABCG2 activity through the activation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells
-
He, X., et al. Hypoxia regulates ABCG2 activity through the activation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells. Cancer. Biol. Ther. 17 (2016), 188–198.
-
(2016)
Cancer. Biol. Ther.
, vol.17
, pp. 188-198
-
-
He, X.1
-
53
-
-
79960989122
-
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors
-
Kummar, S., et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin. Cancer Res. 17 (2011), 5123–5131.
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 5123-5131
-
-
Kummar, S.1
-
54
-
-
84873453721
-
Topoisomerase inhibitors in metastatic breast cancer: overview of current practice and future development
-
Vanderbeeken, M.-C., et al. Topoisomerase inhibitors in metastatic breast cancer: overview of current practice and future development. Curr. Breast Cancer Rep. 5 (2013), 31–41.
-
(2013)
Curr. Breast Cancer Rep.
, vol.5
, pp. 31-41
-
-
Vanderbeeken, M.-C.1
-
55
-
-
84879409543
-
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer
-
Kümler, I., et al. A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer. Breast Cancer Res. Treat. 138 (2013), 347–358.
-
(2013)
Breast Cancer Res. Treat.
, vol.138
, pp. 347-358
-
-
Kümler, I.1
-
56
-
-
84937516442
-
Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function
-
Devriese, L.A., et al. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. Br. J. Clin. Pharmacol. 80 (2015), 253–266.
-
(2015)
Br. J. Clin. Pharmacol.
, vol.80
, pp. 253-266
-
-
Devriese, L.A.1
-
57
-
-
84940956193
-
Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
-
Maeda, H., Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91 (2015), 3–6.
-
(2015)
Adv. Drug Deliv. Rev.
, vol.91
, pp. 3-6
-
-
Maeda, H.1
-
58
-
-
84962711424
-
CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing
-
Clark, A.J., et al. CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 3850–3854.
-
(2016)
Proc. Natl. Acad. Sci. U. S. A.
, vol.113
, pp. 3850-3854
-
-
Clark, A.J.1
-
59
-
-
84883789058
-
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle
-
Eliasof, S., et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 15127–15132.
-
(2013)
Proc. Natl. Acad. Sci. U. S. A.
, vol.110
, pp. 15127-15132
-
-
Eliasof, S.1
-
60
-
-
84862689147
-
Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer
-
Gaur, S., et al. Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. Nanomedicine 8 (2012), 721–730.
-
(2012)
Nanomedicine
, vol.8
, pp. 721-730
-
-
Gaur, S.1
-
61
-
-
84982732971
-
Preclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle-drug conjugate, in treatment of metastatic triple-negative breast cancer
-
Pham, E., et al. Preclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle-drug conjugate, in treatment of metastatic triple-negative breast cancer. Cancer Res. 76 (2016), 4493–4503.
-
(2016)
Cancer Res.
, vol.76
, pp. 4493-4503
-
-
Pham, E.1
-
62
-
-
84923128048
-
Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer
-
Pham, E., et al. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin. Cancer Res. 21 (2015), 808–818.
-
(2015)
Clin. Cancer Res.
, vol.21
, pp. 808-818
-
-
Pham, E.1
-
63
-
-
84857407549
-
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
-
Conley, S.J., et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 2784–2789.
-
(2012)
Proc. Natl. Acad. Sci. U. S. A.
, vol.109
, pp. 2784-2789
-
-
Conley, S.J.1
-
64
-
-
84912151114
-
Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer
-
Gaur, S., et al. Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer. Nanomedicine 10 (2014), 1477–1486.
-
(2014)
Nanomedicine
, vol.10
, pp. 1477-1486
-
-
Gaur, S.1
-
65
-
-
84984977897
-
Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial
-
Keefe, S.M., et al. Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial. Ann. Oncol. 27 (2016), 1579–1585.
-
(2016)
Ann. Oncol.
, vol.27
, pp. 1579-1585
-
-
Keefe, S.M.1
-
66
-
-
85020798998
-
Targeting HIF2 in clear cell renal cell carcinoma
-
Published online December 8, 2016
-
Cho, H., Kaelin, W.G., Targeting HIF2 in clear cell renal cell carcinoma. Cold Spring Harb. Symp. Quant. Biol., 2016, 10.1101/sqb.2016.81.030833 Published online December 8, 2016.
-
(2016)
Cold Spring Harb. Symp. Quant. Biol.
-
-
Cho, H.1
Kaelin, W.G.2
-
67
-
-
85024381247
-
-
CRLX101 in Combination with Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) versus Standard of Care (SOC) (NCT02187302)
-
Anon (2014) CRLX101 in Combination with Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) versus Standard of Care (SOC) (NCT02187302), ClinicalTrials.gov.
-
(2014)
-
-
Anon1
-
68
-
-
80052691602
-
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects
-
Sapra, P., et al. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis, 14, 2011, 245.
-
(2011)
Angiogenesis
, vol.14
, pp. 245
-
-
Sapra, P.1
-
69
-
-
84878651631
-
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer
-
Patnaik, A., et al. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother. Pharmacol. 71 (2013), 1499–1506.
-
(2013)
Cancer Chemother. Pharmacol.
, vol.71
, pp. 1499-1506
-
-
Patnaik, A.1
-
70
-
-
33847421328
-
Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221
-
Creighton-Gutteridge, M., et al. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin. Cancer Res. 13 (2007), 1010–1018.
-
(2007)
Clin. Cancer Res.
, vol.13
, pp. 1010-1018
-
-
Creighton-Gutteridge, M.1
-
71
-
-
85024363817
-
Synergistic inhibition of hypoxia inducible factor-1 (HIF-1) by NSC 644221 in combination with HDAC inhibitors
-
4785–4785
-
Creighton-Gutteridge, M., et al. Synergistic inhibition of hypoxia inducible factor-1 (HIF-1) by NSC 644221 in combination with HDAC inhibitors. Cancer Res., 67, 2007 4785–4785.
-
(2007)
Cancer Res.
, vol.67
-
-
Creighton-Gutteridge, M.1
-
72
-
-
84896032490
-
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors
-
Jeong, W., et al. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors. Cancer Chemother. Pharmacol. 73 (2014), 343–348.
-
(2014)
Cancer Chemother. Pharmacol.
, vol.73
, pp. 343-348
-
-
Jeong, W.1
-
73
-
-
84923684259
-
PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo
-
Pan, X., et al. PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo. Int. J. Mol. Med. 35 (2015), 995–1002.
-
(2015)
Int. J. Mol. Med.
, vol.35
, pp. 995-1002
-
-
Pan, X.1
-
74
-
-
84873091765
-
The VHL/HIF axis in clear cell renal carcinoma
-
Shen, C., Kaelin, W.G., The VHL/HIF axis in clear cell renal carcinoma. Semin. Cancer Biol. 23 (2013), 18–25.
-
(2013)
Semin. Cancer Biol.
, vol.23
, pp. 18-25
-
-
Shen, C.1
Kaelin, W.G.2
-
75
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
-
Sternberg, C.N., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28 (2010), 1061–1068.
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
-
76
-
-
84994626953
-
On-target efficacy of a HIF2α antagonist in preclinical kidney cancer models
-
Cho, H., et al. On-target efficacy of a HIF2α antagonist in preclinical kidney cancer models. Nature 539 (2016), 107–111.
-
(2016)
Nature
, vol.539
, pp. 107-111
-
-
Cho, H.1
-
77
-
-
84994669316
-
Targeting renal cell carcinoma with a HIF-2 antagonist
-
Chen, W., et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539 (2016), 112–117.
-
(2016)
Nature
, vol.539
, pp. 112-117
-
-
Chen, W.1
-
78
-
-
77950815444
-
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer
-
Hashimoto, K., et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol. Cancer Ther. 9 (2010), 996–1006.
-
(2010)
Mol. Cancer Ther.
, vol.9
, pp. 996-1006
-
-
Hashimoto, K.1
-
79
-
-
84927618369
-
Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib
-
Jedeszko, C., et al. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Sci. Transl. Med., 7, 2015, 282ra50.
-
(2015)
Sci. Transl. Med.
, vol.7
, pp. 282ra50
-
-
Jedeszko, C.1
-
80
-
-
77950811722
-
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer
-
Merritt, W.M., et al. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol. Cancer Ther. 9 (2010), 985–995.
-
(2010)
Mol. Cancer Ther.
, vol.9
, pp. 985-995
-
-
Merritt, W.M.1
-
81
-
-
80052495441
-
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor
-
Kumar, S., et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin. Cancer Res. 17 (2011), 5656–5667.
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 5656-5667
-
-
Kumar, S.1
-
82
-
-
67651166780
-
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
-
Rapisarda, A., et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol. Cancer Ther. 8 (2009), 1867–1877.
-
(2009)
Mol. Cancer Ther.
, vol.8
, pp. 1867-1877
-
-
Rapisarda, A.1
-
83
-
-
84896394473
-
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors
-
Jeong, W., et al. Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. Invest. New Drugs 32 (2014), 340–346.
-
(2014)
Invest. New Drugs
, vol.32
, pp. 340-346
-
-
Jeong, W.1
-
84
-
-
84904987878
-
Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor
-
Mésange, P., et al. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget 5 (2014), 4709–4721.
-
(2014)
Oncotarget
, vol.5
, pp. 4709-4721
-
-
Mésange, P.1
-
85
-
-
84907974476
-
2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2
-
Ma, L., et al. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Cancer Lett. 355 (2014), 96–105.
-
(2014)
Cancer Lett.
, vol.355
, pp. 96-105
-
-
Ma, L.1
-
86
-
-
84916912453
-
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab
-
Falchook, G.S., et al. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget 5 (2014), 10280–10292.
-
(2014)
Oncotarget
, vol.5
, pp. 10280-10292
-
-
Falchook, G.S.1
-
87
-
-
84868207640
-
Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α
-
Kim, Y.-J., et al. Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α. Int. J. Cancer 132 (2013), 29–41.
-
(2013)
Int. J. Cancer
, vol.132
, pp. 29-41
-
-
Kim, Y.-J.1
-
88
-
-
84884812874
-
Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3
-
Nagaraju, G.P., et al. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3. Angiogenesis 16 (2013), 903–917.
-
(2013)
Angiogenesis
, vol.16
, pp. 903-917
-
-
Nagaraju, G.P.1
-
89
-
-
79957440961
-
Molecular evolution of the metazoan PHD-HIF oxygen-sensing system
-
Rytkönen, K.T., et al. Molecular evolution of the metazoan PHD-HIF oxygen-sensing system. Mol. Biol. Evol. 28 (2011), 1913–1926.
-
(2011)
Mol. Biol. Evol.
, vol.28
, pp. 1913-1926
-
-
Rytkönen, K.T.1
-
90
-
-
84883501150
-
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
-
Semenza, G.L., HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 123 (2013), 3664–3671.
-
(2013)
J. Clin. Invest.
, vol.123
, pp. 3664-3671
-
-
Semenza, G.L.1
-
91
-
-
59649112848
-
Regulation of angiogenesis by oxygen and metabolism
-
Fraisl, P., et al. Regulation of angiogenesis by oxygen and metabolism. Dev. Cell 16 (2009), 167–179.
-
(2009)
Dev. Cell
, vol.16
, pp. 167-179
-
-
Fraisl, P.1
-
92
-
-
79956328903
-
Molecular mechanisms and clinical applications of angiogenesis
-
Carmeliet, P., Jain, R.K., Molecular mechanisms and clinical applications of angiogenesis. Nature 473 (2011), 298–307.
-
(2011)
Nature
, vol.473
, pp. 298-307
-
-
Carmeliet, P.1
Jain, R.K.2
-
93
-
-
60549092506
-
Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells
-
Lee, K., et al. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 2353–2358.
-
(2009)
Proc. Natl. Acad. Sci. U. S. A.
, vol.106
, pp. 2353-2358
-
-
Lee, K.1
-
94
-
-
79955962513
-
Metabolic reprogramming by HIF-1 promotes the survival of bone marrow-derived angiogenic cells in ischemic tissue
-
Rey, S., et al. Metabolic reprogramming by HIF-1 promotes the survival of bone marrow-derived angiogenic cells in ischemic tissue. Blood 117 (2011), 4988–4998.
-
(2011)
Blood
, vol.117
, pp. 4988-4998
-
-
Rey, S.1
-
95
-
-
84991696421
-
The impact of hypoxia on tumor-associated macrophages
-
Henze, A.-T., Mazzone, M., The impact of hypoxia on tumor-associated macrophages. J. Clin. Invest. 126 (2016), 3672–3679.
-
(2016)
J. Clin. Invest.
, vol.126
, pp. 3672-3679
-
-
Henze, A.-T.1
Mazzone, M.2
-
96
-
-
84946074699
-
Hypoxia: a key player in antitumor immune response
-
Noman, M.Z., et al. Hypoxia: a key player in antitumor immune response. Am. J. Physiol. Cell Physiol. 309 (2015), C569–C579.
-
(2015)
Am. J. Physiol. Cell Physiol.
, vol.309
, pp. C569-C579
-
-
Noman, M.Z.1
-
97
-
-
84911958406
-
Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment
-
Kumar, V., Gabrilovich, D.I., Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology 143 (2014), 512–519.
-
(2014)
Immunology
, vol.143
, pp. 512-519
-
-
Kumar, V.1
Gabrilovich, D.I.2
-
98
-
-
84859700702
-
Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes
-
Skuli, N., et al. Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes. J. Clin. Invest. 122 (2012), 1427–1443.
-
(2012)
J. Clin. Invest.
, vol.122
, pp. 1427-1443
-
-
Skuli, N.1
-
99
-
-
0034032882
-
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
-
Browder, T., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60 (2000), 1878–1886.
-
(2000)
Cancer Res.
, vol.60
, pp. 1878-1886
-
-
Browder, T.1
-
100
-
-
0034087691
-
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
-
Klement, G., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105 (2000), R15–R24.
-
(2000)
J. Clin. Invest.
, vol.105
, pp. R15-R24
-
-
Klement, G.1
-
101
-
-
84929514070
-
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
-
Simkens, L.H.J., et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 385 (2015), 1843–1852.
-
(2015)
Lancet
, vol.385
, pp. 1843-1852
-
-
Simkens, L.H.J.1
-
102
-
-
84962068598
-
Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V
-
Colleoni, M., et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V. J. Clin. Oncol. 34 (2016), 927–935.
-
(2016)
J. Clin. Oncol.
, vol.34
, pp. 927-935
-
-
Colleoni, M.1
-
103
-
-
0024468481
-
DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA
-
Bodley, A., et al. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res. 49 (1989), 5969–5978.
-
(1989)
Cancer Res.
, vol.49
, pp. 5969-5978
-
-
Bodley, A.1
-
104
-
-
70449580319
-
Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
-
Lee, K., et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 17910–17915.
-
(2009)
Proc. Natl. Acad. Sci. U. S. A.
, vol.106
, pp. 17910-17915
-
-
Lee, K.1
-
105
-
-
58149374576
-
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth
-
Zhang, H., et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 19579–19586.
-
(2008)
Proc. Natl. Acad. Sci. U. S. A.
, vol.105
, pp. 19579-19586
-
-
Zhang, H.1
-
106
-
-
33745714060
-
Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A
-
Bielawski, K., et al. Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol. Pharm. Bull. 29 (2006), 1493–1497.
-
(2006)
Biol. Pharm. Bull.
, vol.29
, pp. 1493-1497
-
-
Bielawski, K.1
-
107
-
-
84860389759
-
HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs
-
Zhang, H., et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 31 (2012), 1757–1770.
-
(2012)
Oncogene
, vol.31
, pp. 1757-1770
-
-
Zhang, H.1
|